Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine vs Lidocaine for Quality of Life after Endodontic Treatment
NCT04787731Phase 4Suspended
- Sponsor
- New York University College of Dentistry
- Start
- Jul 2019
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bupivacaine in postoperative pain, pulpitis and pulp necrosis, sponsored by New York University College of Dentistry. Primary endpoint: Oral Health Related Quality-of-Life at 4 weeks. Started Jul 2019; status: suspended.
02
Drugs
bupivacaine
03
Conditions
postoperative painpulpitispulp necrosis
Beyond the preview
Go deeper on NCT04787731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04787731.